• Species Reactivity

  Equine

• Specificity

  Detects equine IL-5 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 50% cross-reactivity with recombinant bovine IL-5 and recombinant feline IL-5 is observed, 30% cross-reactivity with recombinant mouse IL-5 and recombinant canine IL-5 is observed, 20% cross-reactivity with recombinant rhesus macaque IL-5 is observed, and less than 10% cross-reactivity with recombinant rat IL-5 and recombinant porcine IL-5 is observed.

• Source

  Polyclonal Goat IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant equine IL-5    
  Leu20-Gly134    
  Accession # O02699

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Endotoxin Level

  <0.10 EU per 1 μg of the antibody by the LAL method.  

• Label

  Unconjugated

Applications

• 
  

  Recommended    
  Concentration

  Sample

• Western Blot

  0.1 µg/mL

  Recombinant Equine IL‑5 (Catalog # )

• 
  

• Immunocytochemistry

  10-25 µg/mL

  See below

• 
  

• Neutralization

  Measured by its ability to neutralize IL‑5-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T.     et al. (1989) J. Cell Physiol.     140:323. The Neutralization Dose (ND    ₅₀) is typically 0.5-2.0 µg/mL in the presence of 50 ng/mL Recombinant Equine IL‑5.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.2 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-5

Interleukin-5 (IL-5) is a 40 kDa, secreted, heparin-binding, disulfide-linked homodimeric glycoprotein that belongs to the alpha -helical group of cytokines (1‑3). IL-5 is primarily produced by CD4⁺ Th2 cells, but other cell types such as eosinophils, endothelial cells, mast cells, visceral (airway) smooth muscle cells, bronchial epithelium, CD16⁺ NK cells and gamma δ T cells can also produce IL-5. Equine IL-5 is synthesized as a 134 amino acid (aa) precursor that contains a 19 aa signal sequence and a 115 aa mature segment. There are four alpha -helices, two potential N-linked glycosylation sites, and two cysteines that form interchain disulfide bonds with a second, antiparallel IL-5 molecule (3, 4). While human and mouse IL-5 have a potential NLS in their sequence, it is unclear if equine IL-5 has such a sequence. Mature horse IL-5 shares 71%, 89%, 88%, 83%, 66% and 63% aa sequence identity with mature human, bovine, feline, canine, mouse and rat IL-5, respectively.

The receptor for IL-5 consists of a 60 kDa ligand-binding subunit (IL‑5 R alpha ) and a 120 kDa signal-transducing subunit ( beta _c). It is suggested that dimeric IL-5 binding to
IL‑5 R alpha recruits beta _c, which subsequently covalently links with IL‑5 R alpha. This trimeric complex then associates with another trimeric complex to form the physiologic IL-5 receptor (6). Following binding, IL-5 has targeted effects. It promotes the maturation and migration of eosinophils, partially through the effects of eotaxin. It mobilizes eosinophils and CD34⁺ progenitors from marrow. It also enhances Ig release from B cells and contributes to IL-4 production. Finally, it primes basophils for histamine and leukotriene release (1, 2, 7).

• References:

1. Lalani, T. et al. (1999) Ann. Allergy Asthma Immunol. 82:317.

2. Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.  

3. Zabeau, L. et al. (2003) Curr. Drug Targets Inflamm. Allergy 2:319.

4. Vandergrifft, E.V. and D.W. Horohov (1998) GenBank Accession # O02699.

5. Geijsen, N. et al. (2001) Cytokine Growth Factor Rev. 12:19.

6. Bagley, C.J. et al. (1997) Blood 89:1471.

7. Mattes, J. and P.S. Foster (2003) Curr. Drug Targets Inflamm. Allergy 2:169.

• Long Name:

  Interleukin 5

• Entrez Gene IDs:

  3567 (Human); 16191 (Mouse); 24497 (Rat); 397409 (Porcine); 280825 (Bovine); 403790 (Canine); 493803 (Feline)

• Alternate Names:

  BCDF mu; B-cell differentiation factor I; BCGFII; EDF; Eo-CSF; Eosinophil differentiation factor; IL5; IL-5; IL-5T-cell replacing factor; interleukin 5 (colony-stimulating factor, eosinophil); interleukin-5; TRF; TRFB cell differentiation factor I